126 related articles for article (PubMed ID: 34655408)
21. Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.
Lassche G; van Engen-van Grunsven ACH; van Hooij O; Aalders TW; Am Weijers J; Cocco E; Drilon A; Hoischen A; Neveling K; Schalken JA; Verhaegh GW; van Herpen CML
Oral Oncol; 2023 Feb; 137():106297. PubMed ID: 36610231
[TBL] [Abstract][Full Text] [Related]
22. Utility of an immunocytochemical analysis for pan-Trk in the cytodiagnosis of secretory carcinoma of the salivary gland.
Ito H; Ishida M; Ebisu Y; Okano K; Sandoh K; Noda Y; Miyasaka C; Fujisawa T; Yagi M; Iwai H; Tsuta K
Diagn Cytopathol; 2021 Aug; 49(8):E329-E335. PubMed ID: 33885200
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
Boon E; Valstar MH; van der Graaf WTA; Bloemena E; Willems SM; Meeuwis CA; Slootweg PJ; Smit LA; Merkx MAW; Takes RP; Kaanders JHAM; Groenen PJTA; Flucke UE; van Herpen CML
Oral Oncol; 2018 Jul; 82():29-33. PubMed ID: 29909898
[TBL] [Abstract][Full Text] [Related]
24. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
25. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
26. Mammary Analogue Secretory Carcinoma of the Thyroid Mimicking Locally Advanced Papillary Thyroid Carcinoma: A Rare Case Report.
Liao H; Khan A; Miron PM; Cornejo KM
Int J Surg Pathol; 2018 Aug; 26(5):459-463. PubMed ID: 29228842
[TBL] [Abstract][Full Text] [Related]
27. Mammary analog secretory carcinoma of the thyroid gland: A rare cancer harboring TRK fusion.
Huang NS; Cao YM; Lu ZW; Guan Q; Chen JY; Ma B; Chen TZ; Bai QM; Wang YL; Ji QH
Oral Oncol; 2021 Apr; 115():105092. PubMed ID: 33189578
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME
Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737
[TBL] [Abstract][Full Text] [Related]
29. Mammary analog secretory carcinoma of thyroid: A case report.
Rupp AP; Bocklage TJ
Diagn Cytopathol; 2017 Jan; 45(1):45-50. PubMed ID: 27633961
[TBL] [Abstract][Full Text] [Related]
30. Secretory Carcinoma of the Thyroid Gland: Report of a Highly Aggressive Case Clinically Mimicking Undifferentiated Carcinoma and Review of the Literature.
Desai MA; Mehrad M; Ely KA; Bishop JA; Netterville J; Aulino JM; Lewis JS
Head Neck Pathol; 2019 Dec; 13(4):562-572. PubMed ID: 30564997
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic and Molecular Characterization of Four Cases of Pediatric Salivary Secretory Carcinoma (SSC), One with ETV6-RET Fusion.
Salgado CM; Alaggio R; Reyes-Múgica M; Zin A; de Vito R
Head Neck Pathol; 2021 Sep; 15(3):796-802. PubMed ID: 33459993
[TBL] [Abstract][Full Text] [Related]
32. An Underappreciated Cytomorphological Feature of Secretory Carcinoma of Salivary Gland on Fine Needle Aspiration Biopsy: Case Report with Literature Review.
Hua Y; Leng B; Youens KE; Liu L
Head Neck Pathol; 2022 Jun; 16(2):567-572. PubMed ID: 34255277
[TBL] [Abstract][Full Text] [Related]
33. Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6-NTRK3 fusion in both components.
Xu J; Weisman P
Genes Chromosomes Cancer; 2021 Jun; 60(6):447-451. PubMed ID: 33342011
[TBL] [Abstract][Full Text] [Related]
34. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
[TBL] [Abstract][Full Text] [Related]
35. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
36. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity.
Connor A; Perez-Ordoñez B; Shago M; Skálová A; Weinreb I
Am J Surg Pathol; 2012 Jan; 36(1):27-34. PubMed ID: 21989350
[TBL] [Abstract][Full Text] [Related]
37. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.
Guilmette J; Dias-Santagata D; Nosé V; Lennerz JK; Sadow PM
Hum Pathol; 2019 Jan; 83():50-58. PubMed ID: 30130630
[TBL] [Abstract][Full Text] [Related]
38. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
Drilon A; Li G; Dogan S; Gounder M; Shen R; Arcila M; Wang L; Hyman DM; Hechtman J; Wei G; Cam NR; Christiansen J; Luo D; Maneval EC; Bauer T; Patel M; Liu SV; Ou SH; Farago A; Shaw A; Shoemaker RF; Lim J; Hornby Z; Multani P; Ladanyi M; Berger M; Katabi N; Ghossein R; Ho AL
Ann Oncol; 2016 May; 27(5):920-6. PubMed ID: 26884591
[TBL] [Abstract][Full Text] [Related]
39. Secretory carcinoma of salivary gland origin: A recently established masquerader.
Budhiraja S; Kumar R; Khanna G; Sagar P; Arava S; Barwad A; Mridha AR
Indian J Cancer; 2021; 58(2):278-284. PubMed ID: 34100414
[TBL] [Abstract][Full Text] [Related]
40. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion.
Ito Y; Ishibashi K; Masaki A; Fujii K; Fujiyoshi Y; Hattori H; Kawakita D; Matsumoto M; Miyabe S; Shimozato K; Nagao T; Inagaki H
Am J Surg Pathol; 2015 May; 39(5):602-10. PubMed ID: 25651470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
